Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.97 |
| ▸ | ESR1 | P03372 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | ACP1 | P24666 | 1/20 | 0.97 |
| ▸ | PDE4A | P27815 | 1/20 | 0.97 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PNPO | Q9NVS9 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.60 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.58 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | YWHAG | P61981 | 1/20 | 0.44 |
| ▸ | YWHAZ | P63104 | 1/20 | 0.44 |
| ▸ | PDXK | O00764 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxal Phosphate Anhydrous SCHEMBL23158 | 0.99 | P2RX2 (1.00) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29362986 | 0.99 | P2RX2 (1.00) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL827100 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29392551 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL4916108 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL20335524 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL20335516 | 0.97 | P2RX2 (0.97) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL28200961 | 0.93 | ESR1 (0.90) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL10534222 | 0.92 | P2RX2 (0.88) | P2RX2ESR1PTGS1ACP1PDE4A | |
| Pyridoxal Phosphate Anhydrous SCHEMBL29424718 | 0.92 | P2RX2 (0.88) | P2RX2ESR1PTGS1ACP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | claimed |
| US-6444221-B1 | ADMINISTERING AMINOBENZOIC ACID | SECANT PHARMA, LLC | 2002-09-03 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| CN-105492013-A | Compositions for managing nausea and vomiting | DUCHESNAY INC | 2016-04-13 | — | — | CN | disclosed |
| CN-104144690-A | Keratoconjunctiva protective agent or keratoconjunctival disorder inhibitor | TOYO SUGAR REFINING CO LTD | 2014-11-12 | — | — | CN | disclosed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | disclosed |
| WO-2007149815-A1 | STRONTIUM COMPOSITIONS AND METHODS OF TREATING ARTHRITIC AND OR OSTEOPORITIC CONDITIONS | THERAGENEX, LLC (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149816-A2 | STRONTIUM COMPOSITIONS AND METHODS OF TREATING OSTEOPOROTIC CONDITIONS | THERAGENEX, LLC (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-10 | — | — | US | disclosed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | disclosed |
| US-6444221-B1 | ADMINISTERING AMINOBENZOIC ACID | SECANT PHARMA, LLC | 2002-09-03 | — | — | US | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | APP, IAPP, PSEN1 | P2RX2 1574/4885ESR1 4760/4885PTGS1 1276/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | P2RX2 1904/4885ESR1 3419/4885PTGS1 11/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | P2RX2 1774/4885ESR1 3494/4885PTGS1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.